ahro_8k-070912.htm
 
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C.  20549
 
_____________________________
 
FORM 8-K
 
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934
 
Date of Report:
(Date of earliest event reported)
 
July 9, 2012
 
____________________________
 
ATHERONOVA INC.
(Exact name of registrant as specified in charter)
 
Delaware
(State or other Jurisdiction of Incorporation or Organization)
 
000-52315
(Commission File Number)
  
20-1915083
(IRS Employer Identification No.)
     
 
2301 Dupont Drive, Suite 525
Irvine, CA 92612
(Address of Principal Executive Offices and zip code)
  

(949) 476-1100
(Registrant’s telephone
number, including area code)
 
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of registrant under any of the following provisions:
 
[  ]  Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
[  ]  Soliciting material pursuant to Rule 14a-12(b) under the Exchange Act (17 CFR 240.14a-12(b))
[  ]  Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
[  ]  Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
 
 
 
 
 
 
 
Item 8.01.  Other Events.
 
On July 9, 2012, the Registrant issued a press release regarding receipt of a Notice of Allowance from the United States Patent and Trademark Office for its patent application 12/024,908.  The press release is attached as Exhibit 99.1 hereto and is incorporated herein by reference.
 
Item 9.01.  Financial Statements and Exhibits.
 
(d)           Exhibits.
 
 
99.1
Press release entitled “AtheroNova Receives Notice of Allowance for Its US Patent Application 12/024,908” dated July 9, 2012.

 
 
 
 
SIGNATURES
 
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
 
 
AtheroNova Inc.
  
       
Date:  July 11, 2012 
By:
/s/ Mark Selawski  
   
Mark Selawski
Chief Financial Officer & Secretary